论文部分内容阅读
目的:分析生物标志的表达对乳腺浸润性导管癌新辅助化疗(ET方案)疗效的影响。方法:采用免疫组化方法检测112例乳腺浸润性导管癌患者接受表柔比星联合紫杉醇(ET)方案新辅助化疗前肿瘤组织中雌激素受体(ER)、孕激素受体(PR)、c-erbB-2、p53和Ki-67的表达水平。进行多因素Logistic回归分析,评价其对乳腺浸润性导管癌新辅助化疗疗效的相关性。结果:多因素分析显示PR(P=0.0079,OR=0.051)、c-erbB-2(P=0.0321,OR=10.099)和Ki-67(P=0.0212,OR=3.357)3个指标进入Lo-gistic回归方程。多因素分析表明,PR、c-erbB-2和Ki-67与乳腺浸润性导管癌表柔比星联合应用紫杉醇新辅助化疗方案的疗效具有相关性。结论:PR阴性、c-erbB-2阳性、Ki-67阳性乳腺浸润性导管癌患者将在新辅助ET方案中得到最高疗效。
Objective: To analyze the effect of biomarker expression on the efficacy of neoadjuvant chemotherapy for breast invasive ductal carcinoma (ET). Methods: Immunohistochemistry was used to detect the expression of estrogen receptor (ER), progesterone receptor (PR) in 112 patients with invasive ductal carcinoma of the breast before neoadjuvant chemotherapy for epirubicin combined with paclitaxel (ET) c-erbB-2, p53 and Ki-67 expression levels. Multivariate logistic regression analysis was performed to evaluate the correlation between neoadjuvant chemotherapy and breast invasive ductal carcinoma. Results: Multivariate analysis showed that the three indexes of PR (P = 0.0079, OR = 0.051), c-erbB-2 (P = 0.0321, OR = 10.099) and Ki-67 gistic regression equation. Multivariate analysis showed that PR, c-erbB-2 and Ki-67 were associated with the efficacy of neoadjuvant chemotherapy with epirubicin in breast invasive ductal carcinoma. CONCLUSIONS: PR-negative, c-erbB-2-positive patients with Ki-67 positive breast invasive ductal carcinoma will achieve the highest efficacy in neoadjuvant ET regimen.